Q-omics provides the consensus-scored FAM166C profile across patient tissues and cancer cell-line models. FAM166C expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM166C is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, FAM166C RNA expression shows 15,609 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where FAM166C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM166C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM166C survival associations across molecular data types. FAM166C RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM166C RNA expression–survival associations across cancer types. High FAM166C expression shows unfavorable associations in ACC, HNSC, LGG, MESO, UCS and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FAM166C RNA expression.
This table summarizes FAM166C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM166C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM166C shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in COAD, READ and STAD. The COAD box plot shows higher FAM166C RNA expression in tumor versus normal tissue (log2 FC = +2.615, t-test p < 0.001).
This table shows molecular features associated with FAM166C in patient tissues and cancer cell lines. In patient samples, FAM166C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM166C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LUNG_SCLC.
